<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="letter">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Ann Lab Med</journal-id>
      <journal-id journal-id-type="iso-abbrev">Ann Lab Med</journal-id>
      <journal-id journal-id-type="publisher-id">ALM</journal-id>
      <journal-title-group>
        <journal-title>Annals of Laboratory Medicine</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">2234-3806</issn>
      <issn pub-type="epub">2234-3814</issn>
      <publisher>
        <publisher-name>The Korean Society for Laboratory Medicine</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">25932451</article-id>
      <article-id pub-id-type="pmc">4390711</article-id>
      <article-id pub-id-type="doi">10.3343/alm.2015.35.3.376</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Letter to the Editor</subject>
          <subj-group subj-group-type="heading">
            <subject>Diagnostic Hematology</subject>
          </subj-group>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>T618I-Mutated Colony Stimulating Factor 3 Receptor in Chronic Neutrophilic Leukemia and Chronic Myelomonocytic Leukemia Patients who Underwent Allogeneic Stem Cell Transplantation</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Lee</surname>
            <given-names>Sung-Eun</given-names>
          </name>
          <degrees>M.D.</degrees>
          <xref ref-type="aff" rid="A1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Jo</surname>
            <given-names>Irene</given-names>
          </name>
          <degrees>M.D.</degrees>
          <xref ref-type="aff" rid="A2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Jang</surname>
            <given-names>Woori</given-names>
          </name>
          <degrees>M.D.</degrees>
          <xref ref-type="aff" rid="A2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Kim</surname>
            <given-names>Yonggoo</given-names>
          </name>
          <degrees>M.D.</degrees>
          <xref ref-type="aff" rid="A2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Han</surname>
            <given-names>Kyungja</given-names>
          </name>
          <degrees>M.D.</degrees>
          <xref ref-type="aff" rid="A2">2</xref>
        </contrib>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Kim</surname>
            <given-names>Myungshin</given-names>
          </name>
          <degrees>M.D.</degrees>
          <xref ref-type="aff" rid="A2">2</xref>
        </contrib>
      </contrib-group>
      <aff id="A1"><label>1</label>Division of Hematology, Department of Internal Medicine, Seoul St. Mary's Hospital, The Catholic University of Korea, College of Medicine, Seoul, Korea.</aff>
      <aff id="A2"><label>2</label>Department of Laboratory Medicine, Seoul St. Mary's Hospital, The Catholic University of Korea, College of Medicine, Seoul, Korea.</aff>
      <author-notes>
        <corresp>Corresponding author: Myungshin Kim. Department of Laboratory Medicine, Seoul St. Mary's Hospital, The Catholic University of Korea College of Medicine, 222 Banpo-daero, Seocho-gu, Seoul 137-701, Korea. Tel: +82-2-2258-1645, Fax: +82-2-2258-1719, <email>microkim@catholic.ac.kr</email></corresp>
      </author-notes>
      <pub-date pub-type="ppub">
        <month>5</month>
        <year>2015</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>01</day>
        <month>4</month>
        <year>2015</year>
      </pub-date>
      <volume>35</volume>
      <issue>3</issue>
      <fpage>376</fpage>
      <lpage>378</lpage>
      <history>
        <date date-type="received">
          <day>29</day>
          <month>9</month>
          <year>2014</year>
        </date>
        <date date-type="rev-recd">
          <day>09</day>
          <month>10</month>
          <year>2014</year>
        </date>
        <date date-type="accepted">
          <day>28</day>
          <month>1</month>
          <year>2015</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; The Korean Society for Laboratory Medicine.</copyright-statement>
        <copyright-year>2015</copyright-year>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">
          <license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">http://creativecommons.org/licenses/by-nc/3.0/</ext-link>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
        </license>
      </permissions>
      <funding-group>
        <award-group>
          <funding-source country="KR">Ministry of Health and Welfare</funding-source>
          <award-id>A120175</award-id>
        </award-group>
      </funding-group>
    </article-meta>
  </front>
  <body>
    <p>Dear Editor</p>
    <p>Recently, the mutations within the colony-stimulating factor 3 receptor gene (<italic>CSF3R</italic>) have been reported as a specific marker of chronic neutrophilic leukemia (CNL) and atypical CML (aCML) [<xref rid="B1" ref-type="bibr">1</xref>, <xref rid="B2" ref-type="bibr">2</xref>]. The current WHO system classifies CNL as a <italic>BCR-ABL1</italic>-negative myeloproliferative neoplasm (MPN). However, in routine clinical practice, it is difficult to clearly distinguish CNL from aCML, chronic myelomonocytic leukemia (CMML), juvenile myelomonocytic leukemia, and MDS/MPN, unclassifiable under the MDS/MPN umbrella [<xref rid="B3" ref-type="bibr">3</xref>]. Therefore, molecular characteristics (e.g., <italic>CSF3R</italic> mutation) need to be included in the WHO diagnostic criteria. Here, we describe two <italic>CSF3R</italic> T618I-mutated patients with CNL and CMML, respectively, who underwent allogeneic stem cell transplantation (allo-SCT).</p>
    <p>A 40-yr-old man presented in 2012 with marked neutrophilia. His total white blood cell count was 77.24&#xD7;109/L with a differential of 80% neutrophils, 3% band forms, 3% metamyelocytes, 1% myelocytes, 1% promyelocytes, 1% blasts, 3% lymphocytes, and 10% monocytes (<xref ref-type="fig" rid="F1">Fig. 1A</xref>). He had a 23-cm splenomegaly. His bone marrow (BM) aspirate and biopsy showed hypercellularity with granulocytic hyperplasia (<xref ref-type="fig" rid="F1">Fig. 1B</xref>), with a normal karyotype and no evidence of <italic>BCR-ABL1</italic>, <italic>PDGFRA</italic>, or <italic>PDGFRB</italic> rearrangement when examined by FISH. Molecular studies demonstrated the absence of <italic>JAK2</italic> V617F and <italic>BCR-ABL1</italic> transcripts. CNL was diagnosed in accordance with the WHO diagnostic criteria, and the patient was treated with hydroxyurea. However, his neutrophilia persisted in the peripheral blood as anemia and thrombocytopenia developed. Repeated BM examinations showed hypercellular BM with granulocytic hyperplasia and decreased megakaryocytes, and a clonal chromosomal abnormality of 46,XY,der(18:21)(q10;q10),+21[7]/47,+21[5]/46,XY[8]. The <italic>CSF3R</italic> T618I mutation was detected (<xref ref-type="fig" rid="F2">Fig. 2A</xref>). He then underwent myeloablative allo-SCT, using cells from an unrelated donor. At day 35 following the allo-SCT, BM examination showed 70% cellularity with 100% donor chimerism. The T618I mutation was not detected in the BM aspirates through sequencing (<xref ref-type="fig" rid="F2">Fig. 2C</xref>).</p>
    <p>A 60-yr-old man who presented with recurrent purpura on his extremities was referred to our hospital. He had constitutional symptoms including fatigue and weight loss. A computed tomog 
raphy scan of the abdomen demonstrated 13.5-cm mild splenomegaly. His peripheral blood (<xref ref-type="fig" rid="F1">Fig. 1C</xref>) and BM findings (<xref ref-type="fig" rid="F1">Fig. 1D</xref>) were consistent with CMML-1. The patient had a normal karyotype with no evidence of <italic>BCR-ABL1</italic>, <italic>PDGFRA</italic>, or <italic>PDGFRB</italic> rearrangement following FISH examinations. Molecular studies demonstrated the absence of <italic>JAK2</italic> V617F and <italic>BCR-ABL1</italic> transcripts. The <italic>CSF3R</italic> T618I mutation was identified through direct sequencing (<xref ref-type="fig" rid="F2">Fig. 2B</xref>). An initial azacitidine treatment failed to achieve any response. Thus, he underwent allo-SCT using cells from a sibling donor. At day 30 following the allo-SCT, a BM examination showed 30% cellularity with 97% donor chimerism. The <italic>CSF3R</italic> T618I mutation was not detected in the BM aspirates (<xref ref-type="fig" rid="F2">Fig. 2D</xref>).</p>
    <p>Since high-frequency of <italic>CSF3R</italic> mutations in CNL (89%) and, to a lesser extent, in aCML (40%) were discovered [<xref rid="B1" ref-type="bibr">1</xref>, <xref rid="B4" ref-type="bibr">4</xref>], Pardanani et al. [<xref rid="B2" ref-type="bibr">2</xref>] has confirmed that the <italic>CSF3R</italic> T618I mutation was detected exclusively in cases of WHO-defined CNL, with a mutational frequency of 83%. Thus, <italic>CSF3R</italic> T618I mutation should be a diagnostic criterion for CNL.</p>
    <p>Previous studies showed discordant frequencies in the <italic>CSF3R</italic> mutations in CMML and aCML. Maxson et al. [<xref rid="B1" ref-type="bibr">1</xref>] reported that eight of 20 aCML (40%) cases exhibited <italic>CSF3R</italic> mutations, whereas Pardanani et al. [<xref rid="B2" ref-type="bibr">2</xref>] did not find the <italic>CSF3R</italic> mutation in any case of aCML. Although <italic>CSF3R</italic> mutations have been observed in 4% of patients with CMML, they are distinct from membrane proximal mutations; the T618I mutation was identified in a majority of patients with CNL [<xref rid="B5" ref-type="bibr">5</xref>]. However, we observed one CMML patient harboring the <italic>CSF3R</italic> T618I mutation. To incorporate <italic>CSF3R</italic> mutations into the diagnostic criteria of these disorders, the frequency, the location, and the specificity of the <italic>CSF3R</italic> mutations need to be determined.</p>
    <p>Although there is no current standard of care for CNL or for aCML, allo-SCT may be applicable to young patients with potential for blast transformation and progressive refractory neutrophilia [<xref rid="B6" ref-type="bibr">6</xref>,<xref rid="B7" ref-type="bibr">7</xref>,<xref rid="B8" ref-type="bibr">8</xref>,<xref rid="B9" ref-type="bibr">9</xref>]. In our two CNL and CMML patients harboring the <italic>CSF3R</italic> T618I mutation, and who had undergone allo-SCT, the <italic>CSF3R</italic> T618I mutation was not detected following allo-SCT.</p>
    <p>This suggests a predictive role of this mutation in post-transplant relapse, supported by prior studies showing a correlation between post-transplant relapse and the persistence of the <italic>CSF3R</italic> T618I in aCML [<xref rid="B10" ref-type="bibr">10</xref>]. Thus, testing for the <italic>CSF3R</italic> mutation may lead to genetically informed therapy and useful diagnostic approach. The influence of the <italic>CSF3R</italic> mutations on genotype-phenotype associations, disease prognosis, and the efficacy of the therapeutic inhibition of <italic>CSF3R</italic>-related signaling needs to be clarified.</p>
  </body>
  <back>
    <ack>
      <title>Acknowledgments</title>
      <p>The present study was supported by a grant from the Korea Health Technology R&amp;D Project, Ministry of Health &amp; Welfare, Republic of Korea (grant no. A120175).</p>
    </ack>
    <fn-group>
      <fn fn-type="conflict">
        <p><bold>Authors' Disclosures of Potential Conflicts of Interest:</bold> No potential conflicts of interest relevant to this article were reported.</p>
      </fn>
    </fn-group>
    <ref-list>
      <ref id="B1">
        <label>1</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Maxson</surname>
              <given-names>JE</given-names>
            </name>
            <name>
              <surname>Gotlib</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Pollyea</surname>
              <given-names>DA</given-names>
            </name>
            <name>
              <surname>Fleischman</surname>
              <given-names>AG</given-names>
            </name>
            <name>
              <surname>Agarwal</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Eide</surname>
              <given-names>CA</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML</article-title>
          <source>N Engl J Med</source>
          <year>2013</year>
          <volume>368</volume>
          <fpage>1781</fpage>
          <lpage>1790</lpage>
          <pub-id pub-id-type="pmid">23656643</pub-id>
        </element-citation>
      </ref>
      <ref id="B2">
        <label>2</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Pardanani</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Lasho</surname>
              <given-names>TL</given-names>
            </name>
            <name>
              <surname>Laborde</surname>
              <given-names>RR</given-names>
            </name>
            <name>
              <surname>Elliott</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Hanson</surname>
              <given-names>CA</given-names>
            </name>
            <name>
              <surname>Knudson</surname>
              <given-names>RA</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>CSF3R T618I is a highly prevalent and specific mutation in chronic neutrophilic leukemia</article-title>
          <source>Leukemia</source>
          <year>2013</year>
          <volume>27</volume>
          <fpage>1870</fpage>
          <lpage>1873</lpage>
          <pub-id pub-id-type="pmid">23604229</pub-id>
        </element-citation>
      </ref>
      <ref id="B3">
        <label>3</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tefferi</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Thiele</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Vannucchi</surname>
              <given-names>AM</given-names>
            </name>
            <name>
              <surname>Barbui</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <article-title>An overview on CALR and CSF3R mutations and a proposal for revision of WHO diagnostic criteria for myeloproliferative neoplasms</article-title>
          <source>Leukemia</source>
          <year>2014</year>
          <volume>28</volume>
          <fpage>1407</fpage>
          <lpage>1413</lpage>
          <pub-id pub-id-type="pmid">24441292</pub-id>
        </element-citation>
      </ref>
      <ref id="B4">
        <label>4</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gotlib</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Maxson</surname>
              <given-names>JE</given-names>
            </name>
            <name>
              <surname>George</surname>
              <given-names>TI</given-names>
            </name>
            <name>
              <surname>Tyner</surname>
              <given-names>JW</given-names>
            </name>
          </person-group>
          <article-title>The new genetics of chronic neutrophilic leukemia and atypical CML: implications for diagnosis and treatment</article-title>
          <source>Blood</source>
          <year>2013</year>
          <volume>122</volume>
          <fpage>1707</fpage>
          <lpage>1711</lpage>
          <pub-id pub-id-type="pmid">23896413</pub-id>
        </element-citation>
      </ref>
      <ref id="B5">
        <label>5</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kosmider</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Itzykson</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Chesnais</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Lasho</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Laborde</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Knudson</surname>
              <given-names>R</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Mutation of the colony-stimulating factor-3 receptor gene is a rare event with poor prognosis in chronic myelomonocytic leukemia</article-title>
          <source>Leukemia</source>
          <year>2013</year>
          <volume>27</volume>
          <fpage>1946</fpage>
          <lpage>1949</lpage>
          <pub-id pub-id-type="pmid">23774674</pub-id>
        </element-citation>
      </ref>
      <ref id="B6">
        <label>6</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Reilly</surname>
              <given-names>JT</given-names>
            </name>
          </person-group>
          <article-title>Chronic neutrophilic leukaemia: a distinct clinical entity?</article-title>
          <source>Br J Haematol</source>
          <year>2002</year>
          <volume>116</volume>
          <fpage>10</fpage>
          <lpage>18</lpage>
          <pub-id pub-id-type="pmid">11841395</pub-id>
        </element-citation>
      </ref>
      <ref id="B7">
        <label>7</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Breccia</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Biondo</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Latagliata</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Carmosino</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Mandelli</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Alimena</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Identification of risk factors in atypical chronic myeloid leukemia</article-title>
          <source>Haematologica</source>
          <year>2006</year>
          <volume>91</volume>
          <fpage>1566</fpage>
          <lpage>1568</lpage>
          <pub-id pub-id-type="pmid">17043019</pub-id>
        </element-citation>
      </ref>
      <ref id="B8">
        <label>8</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Elliott</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Hanson</surname>
              <given-names>CA</given-names>
            </name>
            <name>
              <surname>Dewald</surname>
              <given-names>GW</given-names>
            </name>
            <name>
              <surname>Smoley</surname>
              <given-names>SA</given-names>
            </name>
            <name>
              <surname>Lasho</surname>
              <given-names>TL</given-names>
            </name>
            <name>
              <surname>Tefferi</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>WHO-defined chronic neutrophilic leukemia: a long-term analysis of 12 cases and a critical review of the literature</article-title>
          <source>Leukemia</source>
          <year>2005</year>
          <volume>19</volume>
          <fpage>313</fpage>
          <lpage>317</lpage>
          <pub-id pub-id-type="pmid">15549147</pub-id>
        </element-citation>
      </ref>
      <ref id="B9">
        <label>9</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hern&#xE1;ndez</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>del Ca&#xF1;izo</surname>
              <given-names>MC</given-names>
            </name>
            <name>
              <surname>Cuneo</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Garc&#xED;a</surname>
              <given-names>JL</given-names>
            </name>
            <name>
              <surname>Guti&#xE9;rrez</surname>
              <given-names>NC</given-names>
            </name>
            <name>
              <surname>Gonz&#xE1;lez</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Clinical, hematological and cytogenetic characteristics of atypical chronic myeloid leukemia</article-title>
          <source>Ann Oncol</source>
          <year>2000</year>
          <volume>11</volume>
          <fpage>441</fpage>
          <lpage>444</lpage>
          <pub-id pub-id-type="pmid">10847463</pub-id>
        </element-citation>
      </ref>
      <ref id="B10">
        <label>10</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Langabeer</surname>
              <given-names>SE</given-names>
            </name>
            <name>
              <surname>McCarron</surname>
              <given-names>SL</given-names>
            </name>
            <name>
              <surname>Haslam</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>O'Donovan</surname>
              <given-names>MT</given-names>
            </name>
            <name>
              <surname>Conneally</surname>
              <given-names>E</given-names>
            </name>
          </person-group>
          <article-title>The CSF3R T618I mutation as a disease-specific marker of atypical CML post allo-SCT</article-title>
          <source>Bone Marrow Transplant</source>
          <year>2014</year>
          <volume>49</volume>
          <fpage>843</fpage>
          <lpage>844</lpage>
          <pub-id pub-id-type="pmid">24614839</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
  <floats-group>
    <fig id="F1" orientation="portrait" position="float">
      <label>Fig. 1</label>
      <caption>
        <title>Chronic neutrophilic leukemia; (A) peripheral blood showing neutrophilia with toxic granulation (Wright-Giemsa staining, &#xD7;1,000) and (B) bone marrow biopsy showing a markedly elevated myeloid:erythroid ratio. Chronic myelomonocytic leukemia (Hematoxylin and eosin staining, &#xD7;1,000); (C) peripheral blood with monocytosis and neutrophilia (Wright-Giemsa staining, &#xD7;400) and (D) bone marrow aspirate with erythroid and granulocytic dysplasia (Wright-Giemsa staining, &#xD7;1,000).</title>
      </caption>
      <graphic xlink:href="alm-35-376-g001"/>
    </fig>
    <fig id="F2" orientation="portrait" position="float">
      <label>Fig. 2</label>
      <caption>
        <title>Sequencing of <italic>genomic</italic> DNA isolated from peripheral blood leukocytes, demonstrating the <italic>CSF3R</italic> c.1853C&gt;T (p.Thr618Ile) mutation. The <italic>CSF3R</italic> T618I mutation was detected in patient #1 with CNL, pre-allo-SCT (A) and in patient #2 with CMML at diagnosis (B). After allo-SCT, the mutation was not detected in patient #1 (C) and in patient #2 (D).</title>
        <p>Abbreviations: CNL, chronic neutrophilic leukemia; allo-SCT, allogeneic stem cell transplantation; CMML, chronic myelomonocytic leukemia.</p>
      </caption>
      <graphic xlink:href="alm-35-376-g002"/>
    </fig>
  </floats-group>
</article>
</pmc-articleset>
